Immunitybio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
IBRX
Immunitybio, INCImmunityBio reports significant revenue growth and multiple international approvals for its lead immunotherapy ANKTIVA, while navigating substantial operating losses, ongoing legal disputes, and the need for additional financing.
NASDAQ
IBRX
Immunitybio, INC10-K: ImmunityBio's 2024 10-K Filing: ANKTIVA Commercialization and Future Pipeline Drive Growth Strategy
ImmunityBio's 2024 10-K highlights the commercialization of ANKTIVA, strategic collaborations, and the advancement of its immunotherapy pipeline to address cancers and infectious diseases.
NASDAQ
IBRX
Immunitybio, INCImmunityBio's annual 10-K filing details its financial status, clinical pipeline, and strategic vision, emphasizing its focus on next-generation immunoand cellular therapies.